Change in h-SDS from start of deferasirox treatment. Change in h-SDS from start of deferasirox treatment to EOS in (A) male and (B) female pediatric patients receiving deferasirox for ≤ 5 years. Age groups refer to age at start of deferasirox treatment. EOS value corresponds to last available value after start of deferasirox for patients aged 2 to < 16 years at the start of deferasirox treatment. Height data for patients aged 2 to < 16 years at the start of deferasirox are included for as long as they remain in the study. Length of the box represents the interquartile range; whiskers extend to minimum and maximum values.